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Abstract
Background: Water displacement leg volumetry is a highly reproducible method, allowing the confirmation of
efficacy of vasoactive substances. Nevertheless errors of its execution and the selection of unsuitable patients are
likely to negatively affect the outcome of clinical studies in chronic venous insufficiency (CVI).
Discussion: Placebo controlled double-blind drug studies in CVI were searched (Cochrane Review 2005, MedLine
Search until December 2007) and assessed with regard to efficacy (volume reduction of the leg), patient
characteristics, and potential methodological error sources. Almost every second study reported only small drug
effects (≤ 30 mL volume reduction). As the most relevant error source the conduct of volumetry was identified.
Because the practical use of available equipment varies, volume differences of more than 300 mL - which is a
multifold of a potential treatment effect - have been reported between consecutive measurements. Other potential
error sources were insufficient patient guidance or difficulties with the transition from the Widmer CVI classification
to the CEAP (Clinical Etiological Anatomical Pathophysiological) grading.
Summary: Patients should be properly diagnosed with CVI and selected for stable oedema and further clinical
symptoms relevant for the specific study. Centres require a thorough training on the use of the volumeter and on
patient guidance. Volumetry should be performed under constant conditions. The reproducibility of short term
repeat measurements has to be ensured.
Background
Various authors have considered water displacement leg
volumetry as a gold standard or reference method for
evaluating therapies working on the venous system of
the lower extremities [1-3]. Optoelectronic methods
building a three-dimensional model of the leg have
advantages because they allow quicker measurements,
but they require complicated machinery and are not
more accurate or more reproducible than water displa-
cement leg volumetry [2]. Simple measurements based
on the frustrum method (i.e. modelling the leg as a sec-
tion of a cone) are quick, but are often regarded as not
very accurate [2].
Water displacement leg volumetry is based on a sim-
ple physical principle. If a leg is immersed into a con-
tainer filled completely to a spout, the volume of
overflowing water represents the volume of the leg, as
f a ra si ti si m m e r s e d .T h eo v e r f l o w nw a t e rc a nb e
weighed or measured in a calibrated container. This
simple principle allows static measurements in resting
patients. More complicated variants have been devel-
oped to measure dynamic leg volume changes during
exercise or rest. When describing their study equipment,
most authors refer to a plethysmograph monitoring con-
tinuous volume changes developed by Thulesius et al.
[4]. However, most studies have actually used modifica-
tions of this specific plethysmograph or devices only sui-
table for static measurements.
We noticed that studies in chronic venous insuffi-
ciency (CVI) using water displacement leg volumetry
with the same or similar drugs had produced dissimilar
results. As we assumed that the way of performing the
study rather than lack of efficacy may have influenced
the outcome [5-10] we performed a selective review of
reports from clinical trials. Our aim was to elucidate
potential error sources of static leg volumetry and to
evaluate their importance for the study result. Based on
our findings we give hints as to how the critical factors * Correspondence: Eberhard.Rabe@ukb.uni-bonn.de
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displacement leg volumetry.
Discussion
Methods
We identified comparative clinical trials on drug thera-
pies for CVI. We considered studies which were placebo
controlled and described as double-blind. Patient popu-
lations were either characterised with the Widmer or
with the CEAP (Clinical Etiological Anatomical Patho-
physiological) classification. The studies evaluated static
volume changes as opposed to dynamic plethysmometry,
and used water displacement volumetry as opposed to
optoelectronic methods. Starting with a Cochrane
review on phlebotonics for venous insufficiency [11] and
a MedLine search up to December 2007 with the key-
words “foot volumetry” or “leg volumetry”,w es u b s e -
quently reviewed the abstracts and hand searched
references in the studies selected this way. Studies with
insufficient information on methodology and/or magni-
tude of effect were excluded. From these papers we
extracted information on effect (reduction of leg
volume), on patient characteristics, on the clinical set-
ting, and on error sources of leg volumetry.
Results
T h eC o c h r a n er e v i e wc o n t a i n e dn=1 5 9r e f e r e n c e sa n d
the MedLine search found n = 74 papers (n = 54 on leg
volumetry and n = 61 on foot volumetry, with overlap-
ping results). We reviewed n = 40 papers in full, where
abstracts or descriptions in referring papers promised
information on treatment effect and/or methodological
aspects, and excluded n = 7, because these expectations
were not met. Eleven publications (see Table 1) con-
tained sufficient data for inclusion in our evaluation of
treatment effects. We excluded the study by Burnand et
al. [12], because it was planned to investigate skin and
tissue oxygenation, not volume changes, and the study
by Cesarone et al. [13], because it was not described as
double-blind. In addition, both studies did not classify
patients according to the Widmer or CEAP scales.
Further two studies included in our evaluation warrant
comment: Danielsson et al. [14] examined foot volume
n o ta tr e s tb u ta f t e r2 0k n e eb e n d s ,s ot h a tt h er e s u l t s
are not fully comparable to the other studies. The study
by Diebschlag et al. underestimates treatment effects
compared to other studies because effects of therapy
were calculated as the volume difference between the
more severely and the less severely affected leg [5]. This
was done to correct “for spontaneous changes in leg
volume, related to variations in temperature, etc.” As
patients were not required to have strictly unilateral
CVI, effects of active therapy on the less affected refer-
ence leg were subtracted during calculation, so that
“these corrected volume changes are less pronounced
than the absolute volume changes”.
1. Magnitude of Effect
The studies in Table 1 found a volume effect of therapy
vs. placebo between +7.5 mL (i.e. a superiority of pla-
cebo) and -100 mL (i.e. a superiority of the active drug).
To facilitate the detection of possible factors that might
influence the magnitude of effect apart from the specific
drug used, we divided the studies into two categories:
Studies showing an only small to moderate effect of
a c t i v ed r u g s ,w h i c hr e d u c e df o o t / l e gv o l u m en o ta ta l l
or by up to 30 mL vs. placebo, and studies reporting a
decrease in volume by more than 30 mL. The former
group, which includes five of the eleven evaluated stu-
dies, is in italics in the table for illustrative purposes.
The cut-off of 30 mL has not been chosen arbitrarily.
Marshall et al. have suggested that a volume reduction
of 30-60 mL vs. placebo is a clinically relevant effect
[15]. The authors estimate the total volume of lower leg
subcutaneous tissues (epifascial space), the potential
space where oedema may accumulate, at approximately
650 mL, with an actual mean oedema volume in CVI of
220 mL [15,16]. Thus, 220 mL is the highest mean
volume that could be mobilised by a maximally effective
therapy and a reduction of 30-60 mL corresponds to
approximately 15-30% of this effect. An effect of this
magnitude is probably clinically relevant, as elastic com-
pression stockings, an accepted standard of care in CVI,
reduced lower leg volumes by 33-89 mL in our panel of
studies and thus to a similar extent (pre-post compari-
sons) [6,8,9].
A current guideline on how studies in CVI patients
should be performed refers to the 30-60 mL border of
clinical relevance, but in addition requires improvements
in clinical symptoms and quality of life [17]. We did not
evaluate the studies in our panel, whether they met this
criterion, because our aim was not a meta-analysis on
the efficacy of drugs used for CVI, but the detection of
error sources in water displacement volumetry.
2. Type of volumeter
Two major subtypes of volumeters are in use. The first
and more common variant, shortly described in the
Introduction, uses a container with an overflow spout.
Water is filled into the container until water flows from
the spout and the water flown over is discarded. There-
after the patient lowers the limb into the container. The
water which now flows from the spout is weighed or its
volume is measured, indicating the volume of the limb
lowered into the container.
The second variant measures the level of the water in
the container, first before the patient lowers the limb
into the container, and again with the limb in the con-
tainer (or vice versa). From a calibration curve
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Page 2 of 9Table 1 Studies with venoactive drugs using water displacement leg/foot volumetry as an efficacy endpoint
First author,
year of publ.
Patients Centres Drug/Reference (No. of
patients with data)
Effect (volume) Comments
Casley-Smith
1988 [33]
CVI Grade [I-]*
III (Widmer)
* not clear
whether I-II
was included
Monocentre,
hospital.
One study
country
(Australia)
Calcium dobesilate (n = 15),
placebo (n = 15).
Treatment duration 6 weeks
-85 mL vs. pbo Change pre-post 4 mL (pbo)
SE ca. 27 mL
Rudofsky 1990
[7]
CVI Grade I-II
(Widmer)
Multicentre.
One study
country
(Germany)
Ruscus + hesperidine-
methylchalcone
(n = 70), placebo (n = 71)
Treatment duration 8 weeks
-47 mL vs. pbo (varicosis)
-65 mL vs. pbo
(postthrombotic syndrome)
Change pre-post ca. +30 mL
(pbo) SE* ca. 6 mL
Vanscheidt
2002a [10]
CVI Grade I-II
(Widmer)
Multicentre.
One study
country
(Germany)
Ruscus extract (n = 77),
placebo (n = 71)
Treatment duration 12 weeks
-21 mL vs. pbo. Change pre-post +6 mL (pbo)
Diebschlag 1994
[5]
CVI Grade II
(Widmer)
Monocentre.
One study
country
(Germany)
Oxerutin 500 and 1000 mg
(n = 2 × 20),
placebo (n = 20).
Treatment duration 12 weeks
-8 and -19 mL vs. pbo (500
and 1000 mg, resp.; corrected
diff. vs. less affected leg)
Change pre-post ± 1 mL (pbo)
SE* ca. 1 mL
Unkauf 1996 [9] CVI Grade II
(Widmer)
Multicentre,
outpatients.
One study
country
(Germany)
Oxerutin (n = 64), placebo
(n = 56); stockings in both
groups.
Treatment duration 12
weeks
-31 mL vs. pbo Change pre-post -33 mL (pbo)
Ihme 1996 [28] CVI Grade I-II
(Widmer)
Monocentre,
hospital.
One study
country
(Germany)
Buckwheat herb tea (n =
36), placebo (n = 31).
Treatment duration 3
months
-78 mL vs. pbo Change pre-post +110 mL
(pbo) SE* ca. 56 mL.
Volumes determined by two
different volumetric
measurements
Vanscheidt
2002b [32]
CVI Grade C3-
C5
(CEAP)
Multicentre,
outpatients.
Multinational
(Germany,
Austria,
Switzerland)
Coumarin + troxerutin (n =
113), placebo (n = 113).
Treatment duration 16 weeks
-30 mL vs. pbo SE ca. 12 mL
Diehm 1996 [6] CVI mainly
Grade I
(Widmer)
Multicentre,
hospital.
Prob. one study
country
(Germany)
HCSE (n = 95), placebo (n =
46),
compression (n = 99).
Treatment duration 12
weeks
-54 mL vs. pbo Change pre-post ca. +10 ± 15
mL (mean ± SE; pbo) and -47 ±
8 mL (compression)
Diehm 2000 (not
published,
according to [8])
CVI Grade II-III
(Widmer)
Multicentre,
hospital.
Prob. one study
country
(Germany)
HCSE (n = 143), placebo (n =
70), compression (n = 142).
Treatment duration 16 weeks
-20 mL vs. pbo Change pre-post ca. +2 ± 10 mL
(mean ± SE* pbo) and -89 ± 10
mL (compression)
Danielsson 2002
[14]
CVI Grade C2-
C4
(-C6) (CEAP)
Monocentre,
hospital.
One study
country (Sweden)
Flavonoids (n = 48), placebo
(n = 49).
Treatment duration 2
months
+7.5 mL vs. pbo Change pre-post +4 mL (pbo)
SE* ca. 4 mL.
Volumetry after 20 knee bends
Kiesewetter
2000 [19]
CVI Grade I-II
(Widmer)
Multicentre,
outpatients.
One study
country
(Germany)
Red vine leaf extract (360
mg: n = 86; 720 mg: n =
84), placebo (n = 87).
Treatment duration 12
weeks
-76 and -100 g vs. pbo (360
and 720 mg, respectively)
Change pre-post ca. +34 g
(pbo).
SE* ca. 10 g
CVI: Chronic venous insufficiency; SE: Standard error; *: SE estimated from published data on group size and standard deviation; pbo: placebo; CEAP: Clinical
Etiological Anatomical Pathophysiological CVI classification; HCSE: Horse chestnut seed extract
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of water levels can be translated into volume changes.
Both types of volumeter possess a comparable preci-
sion in the 0.1-0.2% range for measurements of standard
bodies and in the 0.1-1.0% range for repeated tests of
patients’ limbs [2,3,5,6,15,16,18,19]. In absolute values
and in relation to total lower leg volumes of 2,200-3,200
mL, this corresponds to volumes between approximately
2 and 30 mL. A volume change of 30 mL is already at
the border of clinical relevance as discussed above.
Thus, we advise to test volumeters intended for clinical
studies, to select an instrument with a high precision,
and to optimise procedures until a reproducibility of
short-term measurements in humans better than 20 mL
is obtained. This is a realistic and achievable aim [5,15].
F u r t h e r m o r e ,b e c a u s eo e d e m af o r m a t i o nm a yb ed i f -
ferent in different regions of the lower leg, the height of
the device has to be adequate for the study indication.
For studies in venous patients the water level must be
clearly above the pretibial region, where venous oedema
typically accumulates.
3. The method of leg volume measurements - equipment,
procedures, and study centres
Studies in Table 1 and other publications on methodol-
ogy [18,20-25] describe several error sources in leg volu-
metry. Table 2 presents an overview.
3.1 Positioning of patient during resting and
examination
Changes in the patient’s position during resting or
before examination may result in a major change of leg
volume. If patients rise from a supine to a standing posi-
tion, the hydrostatic pressure rises to approx. 80 mmHg.
This leads to a distension of the veins with an immedi-
ate increase of intravascular volume of approx. 500 mL
[26]. If a sitting patient stands up, hydrostatic pressure
and intravascular volume will change by approx. 30
mmHg and 190 mL, respectively. The volume increase
may be higher in well-trained ("aerobic”)p e r s o n sd u et o
their increased lower leg venous capacity compared to
less trained persons [24]. Pannier could show with the
Perometer method that the leg volume increases after
the change from the supine to the standing position by
app. 2.5%. A steady state is only reached after 10 min-
utes. These rapid changes are mainly due to an intravas-
cular increase of blood volume [27].
In contrast to hydrostatic variations of intravascular
volumes, which occur within minutes, the adaptation of
extravascular volumes to a new postural equilibrium
takes longer. As leg volumetry measures both intra- and
extravascular volumes, experimental procedures should
allow for this adaptation period.
Krijnen et al. observed that in CVI patients with a
standing occupation the leg volume increased by
approximately 80 mL over a full working day [23]. In
healthy volunteers leg volumes reached a slightly smaller
increase (51 ± 32 mL) during 30 minutes of standing
[24].
Taking into account that CVI patients generally show
a larger increase of leg volumes during standing due to
an impaired integrity of their vascular walls, the major
part of extravascular volume adaptation to a new limb
position appears to take place within the first half hour.
Thus we consider this time is a suitable and sufficient
resting and adaptation time for patients before
volumetry.
Water displacement volumeters generally require that
the patient is sitting or standing. One point in favour of
the standing position is the fact that this position imi-
tates “the condition when venous hypertension is acting
on the microcirculation and promoting damage to the
tissue” [20]. However, with a duration of volumetry of
approximately 15-30 minutes per patient [19,21],
repeated measurements may drift to larger values
(approx. +50 mL), if patients are examined in a standing
position [24].
A further consideration supports volumetry in sitting
patients: Due to both the immediate and the prolonged
changes of intra- and extravascular leg volumes induced
by postural changes, it appears important to have the
patients move as little as possible between resting and
volumetry. Because not all persons can tolerate a stand-
ing position over an adaptation period of 30 minutes
[ 2 4 ] ,t h ep a t i e n t ss h o u l ds i td o w nt or e s tf o rn o tl e s s
than 30 minutes before volumetry, with the legs hanging
down. For the examination the patients should ideally
remain seated on the chair they sat during waiting and
they should just lift their leg/s into the volumeter with-
out moving around.
We discourage having patients rest with their legs
crossed, though this has been described in one of the
studies in Table 1 which found a large treatment effect
[19]. Crossing legs impedes venous flow, similar to
Table 2 Error sources in leg volumetry
Methodology
￿ Positioning of patient during resting and examination
￿ Room and water temperature
￿ Exclusion of superficial venous system with tourniquet
￿ Time of investigation
￿ Volumetry procedures
￿ Centres
Indication/Patients
￿ Cardiovascular co-morbidity or co-medication
￿ Other co-medication with volume effects
￿ Diagnosis and grade of CVI
CVI: Chronic venous insufficiency
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using an inflatable cuff show that a cuff increases leg
volumes by approx. 30 mL [1]. The effect of resting
with the legs crossed is non-symmetrical, because it
depends on which leg was the upper leg last before
volumetry.
According to our findings one point has never been
addressed - having patients rest with or without their
shoes and socks/stockings. To avoid any compression,
but also to reduce manipulation and extensive use of
limb muscles during removal of those garments, shoes
and socks/stockings should be removed before the wait-
ing period starts and not directly before volumetry. This
detail is a further confounder, if not described expressly
in the study protocol and if study centres deal with this
aspect differently.
3.2 Room and water temperature
The clinical studies in Table 1 used water temperatures
between 24 and 34°C. This appears reasonable: King
found no noticeable difference in limb volumes at water
temperatures of 20 and 35°C. More extreme tempera-
tures of 5 and 45°C resulted in significant deviations of
1.4% from the normal temperature mean [22]. Thus
changes of water temperature over the duration of the
experiment will not unduly influence volumetry, and a
check - but not a thermostatic control - of water tem-
perature appears sufficient.
We found no data reporting that room temperature
influences volumetry. However, room temperature
should be controlled to an exte n tt h a tp a t i e n t sn e i t h e r
feel cold nor sweat, because these mechanisms of ther-
moregulation will affect the distribution of blood flow
between lower and superficial vessels of leg and foot
and thus volumetry results.
3.3 Exclusion of superficial venous system with
tourniquet
In clinical practice, tourniquets are used in connection
with volumetry to evaluate reflux times in superficial
venous incompetence [13] or to predict the success of
surgery in patients with varicosis [20]. Against this back-
ground, some centres may use tourniquets routinely in
patients undergoing volumetry.
In volumetry studies evaluating the oedema reducing
effect of venoactive drugs tourniquets have no place and
we found no studies to the contrary. Here a tourniquet
would introduce an artificial situation without clinical
relevance. Centres should be educated to observe this
detail, because habitual use of a tourniquet would intro-
duce an easily avoidable bias into the study results.
3.4 Time of investigation
Study protocols generally require patients to return for
visits at approximately the same time of day to avoid
the diurnal variability of leg volumes. Krijnen et al.
found that over the day the leg volume of patients with
major CVI increased by approximately 80 mL [23]. This
corresponds to treatment effects of drugs in CVI, so
that a bias introduced over non-standardised examina-
tion times could completely obliterate therapeutic
effects.
An examination in the morning [5] may be of advan-
tage, because the patients had less opportunity to parti-
cipate in non-standardised activities over the day
influencing leg volumes. On the other hand, oedema
and leg volumes may have “settled” in the afternoon
[19], i.e. change less over hours than in the morning
[18], which decreases variability. We consider the exact
time of examination of minor importance, if this time is
standardised at all.
3.5 Volumetry procedures
Practical use of a volumeter includes major sources of
error. In one unpublished study, which used a volumeter
with an overflow spout, one centre produced deviations
larger than ± 20 ml between two repeated measure-
ments (interval between measurements 5-10 minutes) in
six of seven patients [Rabe, personal communication].
Some deviations were larger than 300 ml. Third repeat
measurements were sometimes close to one of the origi-
nal values, but as often somewhere in between or far
outside the original range. Such differences are not
explained by an imprecision of the instrument or varia-
tions over time. They indicate errors in performing
volumetry and a profound misunderstanding of the pro-
cedures involved.
Three main error sources may be responsible: First,
the containers may not have been fully filled before the
first and/or second measurement, so that the overflow
of water started when the limb was already partially
immersed. This underestimates limb volumes. Second,
water flown over during the initial filling of the con-
tainer was not discarded, but remained in the container
and was added to the water flown over during the mea-
surement. This overestimates limb volumes. Third, the
scales may have been calibrated belatedly while water
was already running from the spout or without the col-
lection container on the scale.
We advise that in absolute values, short term repeated
measurements in patients should be within 10 to < 20
m La n dd e v i a t i o n so f2 0m Lo rm o r es h o u l dl e a dt oa
further repetition and to a review of procedures.
3.6 Centres
Centres may work with erroneous or varying procedures
during volumetry, as stated above. So we expected that
error sources and variability increase in multicentre and
multinational studies and that those studies would less
frequently find volume effects of active therapy which
are > 30 mL. However, from the overview of studies in
Table 1 we could not identify such an effect. Of four
monocentre studies, two each found volume effects ≤ or
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found a volume effect ≤ 30 mL, four an effect > 30 mL
(P = 1.000; Fisher’s exact test). Standard errors of pre-
post changes in the placebo group were between 1 and
56 mL in the monocentre studies and between 6 and 15
mL in the multicentre studies.
We conclude that the error source centre can be over-
come by teaching study staff in detail on the procedures
of the specific volumeter. This is important, as technical
details and procedures for volumeters vary. If centres
have already experience with volumetry and are
recruited for studies, it is likely that this experience has
been gathered with volumeters and measurement proce-
dures different from the study equipment.
Apart from education, performance of centres should
be supervised closely and early. It is advisable to include
volumetry at the screening visit and to monitor each
single measurement (i.e. single values of repeat measure-
ments) immediately either by electronic online forms or
by faxed documentation pages. Centres with inexplicable
deviations can be re-trained or closed, before they intro-
duce major variability into the study.
The volume change during a run-in/wash-out period
should be monitored. Changes depend on the study
design, e.g. on whether compression and/or diuretics are
instituted or ended. Ihme et al. found mean changes of
up to 21 ml over a two-week placebo run-in phase [28].
In the mentioned unpublished study this change was
between 71 and 151 g in one centre [Rabe, personal
communication]. With hindsight, this low performing
centre could have been identified and closed very early
in the study. However, larger volume deviations during
t h er u ni np h a s ec o u l da l s ob ed u et o“unstable”
oedema, for example CVI which is not fully stable or
recent inflammation. In consequence oedema should be
in a steady state before including a patient in a study.
4. The patient - indication, co-diagnoses, patient selection,
and patient characteristics
Vanscheidt et al. have published an international guide-
line describing how to test CVI drugs [17].
4.1 Cardiac co-morbidity or co-medication
Lower limb oedema is a symptom of cardiac diseases.
Oedema of cardiac origin show a considerable diurnal
variation (164 ± 88 mL) [18] and are quickly influenced
by concomitant drugs like diuretics. To avoid confound-
ing of CVI related leg volumes, patients with cardiac co-
morbidity should be strictly excluded from CVI studies.
4.2 Other co-medication with volume effects
Drugs without primary cardiovascular (CV) action such
as non-steroidal anti-inflammatory drugs (NSAIDs) may
also influence limb oedema. They led to clinically mani-
fest oedema in up to 3% of patients and increased mean
body weight by up to 800 g [29,30]. Exclusion of this
possible confounder and education of centres appear
indicated.
4.3 Diagnosis and grade of CVI
Vanscheidt et al. stress the point that clinical examina-
tion is not sufficient to ascertain a reliable diagnosis of
CVI [17]. The disturbances of venous haemodynamics
have to be shown by functional and imaging methods.
Danielsson et al. observe that earlier studies in chronic
venous disease (CVD) “have included patients with all
k i n d so fs y m p t o m sf r o mt h el o w e rl e g ,c o m m o nf o r
patients with CVD, but also present without CVD” [14].
The involvement of the superficial venous system, the
deep venous system, or both should be proven with
objective measures [14]. Venoactive drugs may possess a
different efficacy on CVI of superficial and/or deep
venous origin [7]. Accordingly, in- and exclusion criteria
defining the extent and origin of CVI and tailoring the
patient sample to the properties of the investigational
drug are required. Otherwise the repetition of studies
with one and the same drug is hazardous [6,8], because
the selection of a comparable patient population is not
assured.
We suspect that also the switch from the Widmer to
the CEAP classification for CVI diagnosis could influ-
ence the results of repetitive studies.
The Widmer classification of CVI has been used for
years especially in German speaking countries, the
region where the majority of drug studies in CVI origi-
nates. Most centres that perform such studies are famil-
iar with the Widmer classification and some still classify
their patients according to it. The Widmer classification
has been criticized, because it is based entirely on clini-
cal, morphological criteria (dilated subcutaneous veins
and skin changes) and does not take into account
venous haemodynamics [17]. Variants of the classifica-
tion also include information on oedema [31]) whereas
in the original classification oedema is only a possible
additional sign in all stages.
The CEAP classification includes aetiological, anato-
mical, and pathophysiological information and its con-
struction has been validated. Current guidelines
therefore recommend that patients for CVI studies
should be classified according to the CEAP system [17].
Frequently only the “C” element of the CEAP score is
used. In advanced stages there is little difference in
information between Widmer-based classifications and
the CEAP score, though the scores possess different
numbers (Widmer Stages II correspond to CEAP Class
4, Widmer Stage III corresponds to CEAP Classes 5 and
6). Widmer Stage I defined only by corona phlebectatica
has no clear counterpart in CEAP but may be mixed
with C1. CEAP C3 has no clear counterpart in Widmer
classification as there is no defined “Oedema Stage” but
oedema can be present in Widmer Stages I - III.
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tion scheme can irritate investigators experienced with
another scheme to an extent that they involuntarily and
inadvertently include a different patient population. So
the requirement to recruit patients with oedema and
only mild skin changes (CEAP Grade 3-4a, i.e. Widmer
Grades I-II) could induce investigators to recruit only
Widmer Grade I patients and to exclude Widmer Grade
II with more severe skin changes. Interestingly, the two
studies in Table 1 which used the CEAP classification
showed no relevant drug effect [14,32]. We will follow
up this hypothesis when we report the mentioned
unpublished study.
Conclusions
Water displacement volumetry is a gold standard and
reference method for evaluating lower limb volumes and
the efficacy of venoactive drugs [1-3]. Nevertheless stu-
dies and experience show that it is easier to perform leg
volumetry wrong than right. Error sources can introduce
variations as large as drug effects. This affects sample
size estimates and thus the success of a study, if statisti-
cal significance is missed. Lack of adherence to proce-
dures defined in the study protocol affects the validity of
the measurements or may result in the recruitment of a
different patient sample from planned.
There are some possible errors from the patients’ side.
They may not strictly adhere to requirements on exami-
nation schedules or on body and limb positioning dur-
ing waiting. Furthermore they may not inform the
investigators of concomitant comorbidity or they may
disregard instructions on impermissible concomitant
medication. Accordingly investigators should carefully
select patients with proven reliability regarding drug
intake, accuracy of information provided, and appear-
ance to scheduled examination dates and times. To
achieve and maintain co-operation, it is vital that inves-
tigators inform patients of the detailed study procedures
- at and between visits - and also of the “things that can
go wrong”, if these details are not observed.
Other error sources are within the investigators’
responsibility. There are obvious deviations from the
procedures described in the study protocol, like resting
time and positioning, which introduce errors if not
observed, but they usually should not reach a magnitude
to completely invalidate study results. However, disre-
garding instructions on how to use the volumeter and
on how to perform the examination could have this
effect. We have seen deviating and varying volume mea-
surements that can only be explained by a gross miscon-
ception of the evaluation procedure like calibrating
devices or scales at wrong times or with wrong volumes.
Some of these errors are caused by ordinary carelessness
or by delegation of volumetry to inadequately trained
staff. In addition and probably more importantly, there
is a variety of volumeters which use the same physical
principle - water displacement - but apply different
methods of reading out the results: Water level, weight
of displaced water, volume of displaced water, null value
before lowering the limb into the volumeter or after
removing it. Thus centres using volumetry in clinical
practice or for studies may be familiar with the concept
and a certain type of volumeter, but not with a specific
device selected for a specific study. We see a danger
that out of habit centres may apply their procedures for
their usual volumeter to a different device. This could
result in gross and irreversible errors.
It is the responsibility of the study sponsors to assure
training of investigators and staff. Volumetry should not
only be presented during an investigators’ meeting. It
should be trained in person in the centres in the pre-
sence and with the active participation of the relevant
staff. Sponsors should make sure whether centres are
experienced with other volumeters or other procedures
(e.g. regarding the position of the patient during volu-
metry or the use of a tourniquet) - and if this is the
case, to specifically address such differences. Centres
experienced with other types of volumeter require as
close supervision during the study as centres that use
volumetry for the first time and thus are not influenced
by former habits.
Furthermore, sponsors should ascertain that investiga-
tors understand that the situation in a clinical study dif-
fers from routine practice and requires sufficient
capacity as to time and staff. This capacity is necessary
to identify the right patients, to guide and supervise
them, and to perform volumetry correctly.
We assume that a further highly important error
source within the sponsor’s responsibility is the defini-
t i o no fs t u d yp a t i e n t sa n dt h es u p p l yo fa d e q u a t e
instructions to investigators how to identify exactly
these patients. The switch from the Widmer classifica-
tion of CVI to the CEAP classification with an accepted
transition rule [17] may result in the selection of a dif-
ferent patient population. The only two studies of our
evaluation which used the CEAP classification showed
no relevant drug effect [14,32].
Summary
Successful studies with venoactive drugs in CVI using
lower limb volumetry as an efficacy endpoint require a
multifold approach.
￿ The patients should not only be recruited according
to CEAP grades, but investigators should also receive
clear guidance as to relevant accompanying clinical
symptoms. The exact CVI severity grade to be selected
for the study depends on the drug and its pharmacologi-
cal mode of action.
Rabe et al. BMC Medical Research Methodology 2010, 10:5
http://www.biomedcentral.com/1471-2288/10/5
Page 7 of 9￿ Patients with cardiac co-morbidity and patients
using drugs with effects on the leg volume (like
NSAIDs) should be excluded from CVI studies.
￿ Detailed written and verbal instructions to investiga-
tors on how to perform volumetry are essential. This
includes the task to explain body and limb positioning
during waiting to the patients.
￿ Volumeter and procedures should be optimised until
a reproducibility of short term repeat measurements in
humans better than 20 mL is obtained.
￿ Only trained and certified staff should perform volu-
metry. Close and prompt supervision throughout the
study should be available.
Failure of studies due to unidentified error sources
and inadequate performance is not only an issue of mis-
spending budgets. It is rather an ethical issue, because
patients have in good faith taken on themselves the
risks or discomforts of a study, with the aim to help in
the collection of conclusive data. We hope that our dis-
cussion of error sources in studies using leg volumetry
helps in avoiding some of these pitfalls in future studies.
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